Title
Category
Credits
Event date
Cost
Advancements and Implications of CAR T-Cell Therapy in the Treatment of Hematologic Malignancies
  • Disease management
  • Oncology
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 ASWB - Social Workers
$0.00
This activity will explore advancements in chimeric antigen receptor (CAR) T-cell therapies in treating hematologic malignancies, particularly those of B-cell origin, with a focus on their efficacy and long-term outcomes.
Evolving Strategies and Innovations in Lung Cancer Detection
  • Disease management
  • Oncology
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 ASWB - Social Workers
$0.00
This activity will address the pivotal role of early detection in lung cancer and provide an in-depth look at the latest diagnostic advancements, including traditional methods and emerging technologies.
Active Surveillance and Management of Prostate Cancer
  • Disease management
  • Oncology
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 Attendance - General Attendance
$0.00
This activity will provide an overview of the natural history of early-stage prostate cancer and review current data on the benefits and drawbacks of screening. It will discuss important aspects of diagnosis and describe evidence-based strategies for detection of early-stage prostate cancer.
Bladder Cancer Update: Advances in Treatment and the Role of Early Diagnosis
  • Oncology
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
This activity will provide participants with an overview of early BC diagnosis and its impact on survival rates. It will explore recently approved therapies for BC both as standalone treatments and in combination with established therapeutic approaches. Emerging therapies and their potential benefits will be examined, and the value of biomarkers will be discussed. Participants will gain insight into treatment strategies to optimize patient outcomes in BC.